Q linea AB (QLINEA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Q linea AB (QLINEA) has a cash flow conversion efficiency ratio of -0.099x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-30.19 Million ≈ $-3.25 Million USD) by net assets (Skr304.55 Million ≈ $32.77 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See QLINEA equity to assets ratio to measure how much of total assets are equity-financed.
Q linea AB - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how Q linea AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore Q linea AB long-term investment allocation to see how much of total assets are deployed in long-term investments.
Q linea AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Q linea AB ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Chi Hua Fitness Co Ltd
TWO:1593
|
0.029x |
|
Turism Hotelur
RO:EFO
|
N/A |
|
Duck Yang Ind
KO:024900
|
0.098x |
|
Canacol Energy Ltd.
TO:CNE
|
0.124x |
|
Changchai Co Ltd
SHE:200570
|
-0.017x |
|
Haverty Furniture Companies Inc
NYSE:HVT-A
|
0.104x |
|
Integrated Research Ltd
AU:IRI
|
0.097x |
|
Sealink International Bhd
KLSE:5145
|
-0.080x |
Annual Cash Flow Conversion Efficiency for Q linea AB (2016–2025)
The table below shows the annual cash flow conversion efficiency of Q linea AB from 2016 to 2025. For the full company profile with market capitalisation and key ratios, see how much is Q linea AB worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Skr338.00 Million ≈ $36.37 Million |
Skr-162.12 Million ≈ $-17.45 Million |
-0.480x | -107.22% |
| 2024-12-31 | Skr-27.46 Million ≈ $-2.95 Million |
Skr-182.50 Million ≈ $-19.64 Million |
6.647x | +651.58% |
| 2023-12-31 | Skr189.64 Million ≈ $20.41 Million |
Skr-228.52 Million ≈ $-24.59 Million |
-1.205x | +22.36% |
| 2022-12-31 | Skr161.63 Million ≈ $17.39 Million |
Skr-250.86 Million ≈ $-27.00 Million |
-1.552x | -162.15% |
| 2021-12-31 | Skr430.79 Million ≈ $46.36 Million |
Skr-255.05 Million ≈ $-27.45 Million |
-0.592x | +5.14% |
| 2020-12-31 | Skr380.20 Million ≈ $40.92 Million |
Skr-237.31 Million ≈ $-25.54 Million |
-0.624x | -25.36% |
| 2019-12-31 | Skr340.94 Million ≈ $36.69 Million |
Skr-169.76 Million ≈ $-18.27 Million |
-0.498x | -108.34% |
| 2018-12-31 | Skr513.46 Million ≈ $55.26 Million |
Skr-122.71 Million ≈ $-13.21 Million |
-0.239x | +99.43% |
| 2017-12-31 | Skr1.51 Million ≈ $162.72K |
Skr-62.87 Million ≈ $-6.77 Million |
-41.577x | -565.28% |
| 2016-12-31 | Skr8.45 Million ≈ $909.79K |
Skr-52.83 Million ≈ $-5.69 Million |
-6.250x | -- |
About Q linea AB
Q-linea AB (publ) engages in the manufacturing and sale of instruments and consumables diagnose and treat infectious diseases in the United Kingdom, the United States, France, the Middle East, Belgium, Italy, and Finland. It offers ASTar, an antimicrobial susceptibility testing (AST) technology used in the treatment of bloodstream infections and sepsis; and ASTar BC G- Kit which contains two disp… Read more